標(biāo)題: Titlebook: Cancer Therapeutic Targets; John L. Marshall Reference work 2017 Springer Science+Business Media New York 2017 Anti-angiogenic Targets.HER [打印本頁(yè)] 作者: 迅速 時(shí)間: 2025-3-21 16:28
書(shū)目名稱(chēng)Cancer Therapeutic Targets影響因子(影響力)
作者: 捐助 時(shí)間: 2025-3-21 21:40
http://image.papertrans.cn/c/image/221210.jpg作者: 大笑 時(shí)間: 2025-3-22 01:07
Schlussfolgerungen und Ausblick,tor (HER) family, which includes EGFR (or HER1), HER2, HER3, and HER4. EGFR is expressed in a variety of cell types, but primarily cells of epithelial, mesenchymal, and neuronal origin. It has been shown to be critical in the development of epithelial cancers, and EGFR overexpression or constitutive action can promote angiogenesis and metastasis.作者: 跳脫衣舞的人 時(shí)間: 2025-3-22 08:20 作者: Perigee 時(shí)間: 2025-3-22 12:12
CTLA-4This is a brief summary of the biologic basis for use of CTLA-4 blockade in the treatment of cancer, specifically melanoma and renal cell carcinoma. Included is the biology of CTLA-4, the preclinical and clinical studies to date. Lastly, the future goals and directions of CTLA-4 are discussed including combination with newer immunotherapies.作者: KIN 時(shí)間: 2025-3-22 15:54
EGFR, Immunologytor (HER) family, which includes EGFR (or HER1), HER2, HER3, and HER4. EGFR is expressed in a variety of cell types, but primarily cells of epithelial, mesenchymal, and neuronal origin. It has been shown to be critical in the development of epithelial cancers, and EGFR overexpression or constitutive action can promote angiogenesis and metastasis.作者: KIN 時(shí)間: 2025-3-22 20:19
https://doi.org/10.1007/978-1-4419-0717-2Anti-angiogenic Targets; HER2/EGFR Targets; Nuclear Receptors; Hormone Receptors; Heme作者: 態(tài)學(xué) 時(shí)間: 2025-3-22 23:30 作者: jabber 時(shí)間: 2025-3-23 03:54 作者: opprobrious 時(shí)間: 2025-3-23 06:12 作者: 合唱隊(duì) 時(shí)間: 2025-3-23 10:07 作者: LUT 時(shí)間: 2025-3-23 17:44
https://doi.org/10.1007/978-3-8348-9964-4are associated with increased angiogenesis and systemic inflammation. High levels of the ligand alone are also associated with poorer tumor outcomes. However, increased levels of both the ligand and receptor are associated with increased tumor antigen presentation by antigen presenting cells and hav作者: 組裝 時(shí)間: 2025-3-23 18:51 作者: 悶熱 時(shí)間: 2025-3-24 01:51 作者: conifer 時(shí)間: 2025-3-24 03:31
Eckart Laurien,Herbert Oertel jr.id tumors (Lenschow et al., Annu Rev Immunol 14:233–258, 1996). Nevertheless, B7-1 has been shown to be essential for the induction of T-cell responses, which play a central role in mediating tumor immunosurveillance and immune-mediated tumor regression (Ward and Kaufman, Int Rev Immunol 26:161–196,作者: Decimate 時(shí)間: 2025-3-24 07:40
Eckart Laurien,Herbert Oertel jr.rplay, as well as the recent advances in genetic engineering. Safe, targeted therapies are being developed, in which genetically-modified pathogens are designed to trigger effective anti-tumor immune response. Here we describe the bacterial strains intended for cancer immunotherapies, the genetic mo作者: Rheumatologist 時(shí)間: 2025-3-24 13:14
Hinweise zu den Visual C#-Programmeng the metastasis of solid tumors. The phenotypic switch, termed epithelial-to-mesenchymal transition (EMT), has also been associated with resistance of carcinoma cells to chemotherapy, radiation, and some small-molecule-targeted therapies. Brachyury is a T-box transcription factor that has recently 作者: micturition 時(shí)間: 2025-3-24 16:31 作者: Awning 時(shí)間: 2025-3-24 21:44
https://doi.org/10.1007/978-3-642-17208-3 cytokines and expression of distinct intracellular transcription factors and surface chemokine receptors. The functional diversity of T cells is demonstrated by the association of certain CD4+ T cell types (including Th1 CD4+ T cells) with positive cancer prognosis and other CD4+ T cell types (incl作者: Indolent 時(shí)間: 2025-3-25 02:43 作者: 夸張 時(shí)間: 2025-3-25 06:08
https://doi.org/10.1007/978-3-662-38531-92, 1965b). This 180,000?Da glycoprotein earned its name due to its presence in neoplastic and embryonic gastrointestinal tissues (Martin et al., Cancer 37:62–81, 1976). CEA is overexpressed on most adenocarcinomas of the colon, rectum, stomach, and pancreas, as well as breast cancers and non-small c作者: cacophony 時(shí)間: 2025-3-25 07:31
https://doi.org/10.1007/978-3-642-82968-0heir long projections that made them resemble the dendrites of nerve cells, which was the function Langerhans assigned to them at that time. The true role of DCs as powerful antigen-presenting cells (APC) was elucidated by Ralph Steinman in 1973, in studies that ultimately led to the award of a Nobe作者: 卵石 時(shí)間: 2025-3-25 12:33 作者: HIKE 時(shí)間: 2025-3-25 16:25
Schlussfolgerungen und Ausblick,tor (HER) family, which includes EGFR (or HER1), HER2, HER3, and HER4. EGFR is expressed in a variety of cell types, but primarily cells of epithelial, mesenchymal, and neuronal origin. It has been shown to be critical in the development of epithelial cancers, and EGFR overexpression or constitutive作者: 關(guān)節(jié)炎 時(shí)間: 2025-3-25 21:13
,Simulation Laborrührer Scaba 6SRGT, (cetuximab), have shown remarkable activity in the clinic against a wide range of malignancies and are now part of standard treatment protocols. The activity of IgG antibodies is regulated in part by a diverse family of Fc gamma receptors (FcγR), which bind to the constant Fc region of IgG antibodi作者: DENT 時(shí)間: 2025-3-26 03:03
regular updates.Provides expert editors’ overviews for each .In the past decade, we have experienced an explosion of new information about cancer therapeutic targets. Many of the targets have been validated by the discovery and approval of new medicines which have been approved for the treatment of 作者: 有偏見(jiàn) 時(shí)間: 2025-3-26 04:48
Diskretisierung der Transportgleichungen,ne kinases in response to various growth factors. AKT is a serine/threonine kinase located at the apex of a cascade of signaling pathways. Deregulated AKT signaling is implicated in cancer cell growth, proliferation, and survival. Novel antitumor strategies have now been developed to target AKT and key downstream targets in the clinic.作者: cogent 時(shí)間: 2025-3-26 09:35 作者: TATE 時(shí)間: 2025-3-26 16:09
Eckart Laurien,Herbert Oertel jr.s, which play a central role in mediating tumor immunosurveillance and immune-mediated tumor regression (Ward and Kaufman, Int Rev Immunol 26:161–196, 2007). B7-1 consequently plays an important role in cancer vaccines that focus on harnessing the potential of the host immune system to recognize and eradicate malignant tumors.作者: 單挑 時(shí)間: 2025-3-26 17:39
Hinweise zu den Visual C#-Programmen. Recent clinical trials using both purified tumor infiltrating lymphocytes (TILs) as well as the novel chimeric antigen receptor T cells (CAR T cells) have shown great promise in the treatment of a variety of neoplasias including melanoma, and leukemias. Many clinical trials are now ongoing to elucidate the potential of these new therapies.作者: Ablation 時(shí)間: 2025-3-26 22:55 作者: 輕快走過(guò) 時(shí)間: 2025-3-27 02:21
Anti-B7-H47-H4 up-regulation has shown to be associated with diseases progression and/or outcome in some cancers. The unique expression of B7-H4 in the tumor microenvironment and its potential immune inhibitory functions on both innate and adaptive immune responses represents a novel target for the next-generation cancer diagnosis and immunotherapy.作者: resistant 時(shí)間: 2025-3-27 07:50
B7.1s, which play a central role in mediating tumor immunosurveillance and immune-mediated tumor regression (Ward and Kaufman, Int Rev Immunol 26:161–196, 2007). B7-1 consequently plays an important role in cancer vaccines that focus on harnessing the potential of the host immune system to recognize and eradicate malignant tumors.作者: 許可 時(shí)間: 2025-3-27 10:05 作者: GLADE 時(shí)間: 2025-3-27 17:34 作者: 合適 時(shí)間: 2025-3-27 21:13
Bacterial Vaccinesdifications that attenuate their pathogenicity but strengthen anti-tumor potential and the desirable mechanisms of actions. The only FDA approved .-based cancer therapy as well as numerous examples of ongoing clinical trials involving different bacterial strains are presented.作者: 吵鬧 時(shí)間: 2025-3-28 01:27
CCL21. Based on the findings on CCL21, it is anticipated that rational combinations with other treatment modalities will improve the therapeutic efficacy of this chemokine and antitumor benefit in a broad range of solid tumors.作者: 晚來(lái)的提名 時(shí)間: 2025-3-28 03:38
Dendritic Cellsl Prize in 2011. These cells play a vital role in our immune system, covering both innate and adaptive immune responses, and come from a variety of lineages and have various locations (Kuby et al., Immunology, 6th edn. W.H. Freeman, New York, 2007).作者: exercise 時(shí)間: 2025-3-28 09:09
Herbert Oertel jr.,Eckart Lauriene other members of the tumor necrosis factor superfamily, the ecto-domain of 4-1BB forms a homotrimer with an extended, three-bladed propeller structure (Won et al. 2010). 4-1BB also has a cysteine-rich extracellular domain, a transmembrane region, and a cytoplasmic domain that contains a tyrosine kinase p56. binding site (Vinay and Kwon 2006).作者: Ligneous 時(shí)間: 2025-3-28 13:50 作者: Substance-Abuse 時(shí)間: 2025-3-28 17:42
Anti-4-1BB/4-1BBLe other members of the tumor necrosis factor superfamily, the ecto-domain of 4-1BB forms a homotrimer with an extended, three-bladed propeller structure (Won et al. 2010). 4-1BB also has a cysteine-rich extracellular domain, a transmembrane region, and a cytoplasmic domain that contains a tyrosine kinase p56. binding site (Vinay and Kwon 2006).作者: 浪費(fèi)時(shí)間 時(shí)間: 2025-3-28 22:12
Anti-CD40/Anti-CD40Ls with melanoma having the best outcomes, with a minority of patients having some responses. Cytokine release syndrome was the most common adverse event. Rational combinations of cytokines with the use of novel immunotherapies targeting CD40 may show promise in the treatment of neoplastic disease.作者: 先鋒派 時(shí)間: 2025-3-29 02:07 作者: nepotism 時(shí)間: 2025-3-29 06:59 作者: 變形 時(shí)間: 2025-3-29 07:50 作者: 上下連貫 時(shí)間: 2025-3-29 12:35
Eckart Laurien,Herbert Oertel jr.difications that attenuate their pathogenicity but strengthen anti-tumor potential and the desirable mechanisms of actions. The only FDA approved .-based cancer therapy as well as numerous examples of ongoing clinical trials involving different bacterial strains are presented.作者: lacrimal-gland 時(shí)間: 2025-3-29 18:52 作者: GENUS 時(shí)間: 2025-3-29 21:57 作者: PANIC 時(shí)間: 2025-3-30 03:26
Diskretisierung des Berechnungsgebietsuppressive tumor microenvironment (Brown et al., J Immunol 170:1257–1266, 2003; Dong et al., Nat Med 8:793–800, 2002; Driessens et al., Immunol Rev 229:126–144, 2009; Wang and Chen, Curr Top Microbiol Immunol, n.d.).作者: trigger 時(shí)間: 2025-3-30 06:41
Anti-Programmed Death 1 (PD1)uppressive tumor microenvironment (Brown et al., J Immunol 170:1257–1266, 2003; Dong et al., Nat Med 8:793–800, 2002; Driessens et al., Immunol Rev 229:126–144, 2009; Wang and Chen, Curr Top Microbiol Immunol, n.d.).作者: Eeg332 時(shí)間: 2025-3-30 12:13 作者: 尋找 時(shí)間: 2025-3-30 12:21
CD4+ T Cellsn generating anti-tumor CD4+ T cell responses have been met with limited success. However, new approaches including Chimeric Antigen Receptors (CARs) may be increase the viability of CD4+ T cells as a potential therapeutic modality in the treatment of cancer.作者: ostensible 時(shí)間: 2025-3-30 17:05 作者: Ligneous 時(shí)間: 2025-3-30 22:23 作者: 免費(fèi) 時(shí)間: 2025-3-31 03:08 作者: 我怕被刺穿 時(shí)間: 2025-3-31 05:28 作者: Microgram 時(shí)間: 2025-3-31 09:57 作者: 技術(shù) 時(shí)間: 2025-3-31 15:53 作者: kidney 時(shí)間: 2025-3-31 20:17
https://doi.org/10.1007/978-3-662-38531-9d on normal granulocytes (Engvall et al., Proc Natl Acad Sci U S A 75:1670–1674, 1978). As an intercellular adhesion molecule, CEA may contribute to the formation of metastasis; there is a correlation between serum CEA in patients with cancer and the incidence of hepatic metastases, but this could a作者: 琺瑯 時(shí)間: 2025-4-1 00:47 作者: 壓倒 時(shí)間: 2025-4-1 03:47 作者: 刪除 時(shí)間: 2025-4-1 08:17 作者: 摻假 時(shí)間: 2025-4-1 14:01 作者: prodrome 時(shí)間: 2025-4-1 15:17
Anti-B7-H4H4 protein expression is generally absent in peripheral tissues but is increased on many cancer cells or tumor-associated immune cells. In addition, B7-H4 up-regulation has shown to be associated with diseases progression and/or outcome in some cancers. The unique expression of B7-H4 in the tumor mi
